Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 302

Results For "CRE"

4819 News Found

Teijin and Axcelead to establish drug discovery research JV
News | February 21, 2023

Teijin and Axcelead to establish drug discovery research JV

The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.


India achieves 15,000+ transplants in a year
News | February 20, 2023

India achieves 15,000+ transplants in a year

There is a fast resurgence in the transplant activities post COVID


USFDA accepts for priority review the sNDA for Merck’s Prevymis
Drug Approval | February 18, 2023

USFDA accepts for priority review the sNDA for Merck’s Prevymis

FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients


IAGES collaborates with technology leaders in robotic surgery
News | February 18, 2023

IAGES collaborates with technology leaders in robotic surgery

IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023


Asahi Kasei completes construction of microcrystalline cellulose plant
News | February 18, 2023

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC


Patient care is an imperative dimension in providing quality healthcare: Dr. Bharati Pravin Pawar
News | February 18, 2023

Patient care is an imperative dimension in providing quality healthcare: Dr. Bharati Pravin Pawar

The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals


Biocon Q3 FY23 revenue up 36%
News | February 17, 2023

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses


Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData
News | February 17, 2023

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year


GUERISON enters Indian Ophthalmology market
News | February 17, 2023

GUERISON enters Indian Ophthalmology market

The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes


Lonza completes expansion of conjugation facility in Visp
News | February 17, 2023

Lonza completes expansion of conjugation facility in Visp

The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates